Cargando…

Combined heterozygosity of FLT3(ITD), TET2, and DNMT3A results in aggressive leukemia

Heterozygous mutations in FLT3(ITD), TET2, and DNMT3A are associated with hematologic malignancies in humans. In patients, cooccurrence of mutations in FLT3(ITD) combined with TET2 (TF) or FLT3(ITD) combined with DNMT3A (DF) are frequent. However, in some rare complex acute myeloid leukemia (AML), a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ramdas, Baskar, Lakshmi Reddy, Palam, Mali, Raghuveer Singh, Pasupuleti, Santhosh Kumar, Zhang, Ji, Kelley, Mark R., Paczesny, Sophie, Zhang, Chi, Kapur, Reuben
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9536269/ https://www.ncbi.nlm.nih.gov/pubmed/36073548 http://dx.doi.org/10.1172/jci.insight.162016

Ejemplares similares

Loss of Dnmt3a impairs hematopoietic homeostasis and myeloid cell skewing via the PI3Kinase pathway
por: Palam, Lakshmi Reddy, et al.
Publicado: (2023)

Driver Mutations in Leukemia Promote Disease Pathogenesis through a Combination of Cell-Autonomous and Niche Modulation
por: Ramdas, Baskar, et al.
Publicado: (2020)

Syk kinase and Shp2 phosphatase inhibition cooperate to reduce FLT3-ITD-induced STAT5 activation and proliferation of acute myeloid leukemia
por: Richine, Briana M., et al.
Publicado: (2016)

Physioxia-induced downregulation of Tet2 in hematopoietic stem cells contributes to enhanced self-renewal
por: Aljoufi, Arafat, et al.
Publicado: (2022)

Copy-neutral loss of heterozygosity is prevalent and a late event in the pathogenesis of FLT3/ITD AML
por: Stirewalt, D L, et al.
Publicado: (2014)

Consecutive epigenetically-active agent combinations act in ID1-RUNX3-TET2 and HOXA pathways for Flt3ITD+ve AML
por: Sayar, Hamid, et al.
Publicado: (2017)

Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models
por: Mali, Raghuveer Singh, et al.
Publicado: (2020)

Dnmt3a deletion cooperates with the Flt3/ITD mutation to drive leukemogenesis in a murine model
por: Poitras, Jennifer L., et al.
Publicado: (2016)

The Protein Tyrosine Phosphatase, Shp2, Positively Contributes to FLT3-ITD-Induced Hematopoietic Progenitor Hyperproliferation and Malignant Disease In Vivo
por: Nabinger, Sarah C., et al.
Publicado: (2012)

getITD for FLT3-ITD-based MRD monitoring in AML
por: Blätte, Tamara J., et al.
Publicado: (2019)

Role of intracellular tyrosines in activating KIT induced myeloproliferative disease
por: Ma, Peilin, et al.
Publicado: (2012)

Imipramine blue sensitively and selectively targets FLT3-ITD positive acute myeloid leukemia cells
por: Metts, Jonathan, et al.
Publicado: (2017)

Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML
por: Wang, Aoli, et al.
Publicado: (2016)

Arsenic trioxide induces autophagic degradation of the FLT3-ITD mutated protein in FLT3-ITD acute myeloid leukemia cells
por: Liu, Xiao-Jian, et al.
Publicado: (2020)

Haemophagocytic lymphohistiocytosis occurred during induction chemotherapy in an acute monocytic leukemia patient with FLT3-ITD and DNMT3A mutations
por: Li, Fei, et al.
Publicado: (2018)

Il-1r1 drives leukemogenesis induced by Tet2 loss
por: Burns, Sarah S., et al.
Publicado: (2022)

Inhibition of BTK and PI3Kδ impairs the development of human JMML stem and progenitor cells
por: Ramdas, Baskar, et al.
Publicado: (2022)

Single Nucleotide Polymorphism Array Lesions, TET2, DNMT3A, ASXL1 and CBL Mutations Are Present in Systemic Mastocytosis
por: Traina, Fabiola, et al.
Publicado: (2012)

The GSK3β/Mcl-1 axis is regulated by both FLT3-ITD and Axl and determines the apoptosis induction abilities of FLT3-ITD inhibitors
por: Qiu, Yang, et al.
Publicado: (2023)

Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3
por: Nagai, Kozo, et al.
Publicado: (2018)

Unique and redundant roles of class I(A) PI3Kinase regulatory subunits in mast cell development
por: Mali, Raghuveer Singh, et al.
Publicado: (2013)

RUNX1 cooperates with FLT3-ITD to induce leukemia
por: Behrens, Kira, et al.
Publicado: (2017)

Wild‐type FLT3 and FLT3 ITD exhibit similar ligand‐induced internalization characteristics
por: Kellner, Fabienne, et al.
Publicado: (2020)

Mutation Analysis of JAK2V617F, FLT3-ITD, NPM1, and DNMT3A in Chinese Patients with Myeloproliferative Neoplasms
por: Wang, Min, et al.
Publicado: (2014)

The Impact of DNMT3A/FLT3-ITD/NPM1 on Patients with Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
por: Su, Long
Publicado: (2019)

Gilteritinib as treatment for extra-medullary relapse of FLT3-ITD acute myeloid leukemia FLT3-ITD, after allogeneic haematopoietic stem cell transplantation
por: Iannotta, R., et al.
Publicado: (2022)

Class I(A) PI3Kinase Regulatory Subunit, p85α, Mediates Mast Cell Development through Regulation of Growth and Survival Related Genes
por: Krishnan, Subha, et al.
Publicado: (2012)

A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia
por: Lee, Lauren Y., et al.
Publicado: (2021)

FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML
por: Kivioja, Jarno, et al.
Publicado: (2021)

Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
por: Xu, Dan, et al.
Publicado: (2022)

How ITD Insertion Sites Orchestrate the Biology and Disease of FLT3-ITD-Mutated Acute Myeloid Leukemia
por: Haage, Tobias R., et al.
Publicado: (2023)

Overcoming AC220 resistance of FLT3-ITD by SAR302503
por: Kesarwani, M, et al.
Publicado: (2013)

Maintenance therapy for FLT3-ITD-mutated acute myeloid leukemia
por: Burchert, Andreas
Publicado: (2021)

MicroRNA networks in FLT3-ITD acute myeloid leukemia
por: Hoang, Dinh Hoa, et al.
Publicado: (2022)

Lack of FLT3-ITD in Tunisian childhood acute lymphoblastic leukemia
por: Frikha, Rim, et al.
Publicado: (2022)

Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia
por: Green, Alexa S., et al.
Publicado: (2015)

Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD(+) AML cell growth
por: Weir, Mark C., et al.
Publicado: (2017)

CCL5 mediates target‐kinase independent resistance to FLT3 inhibitors in FLT3‐ITD‐positive AML
por: Waldeck, Silvia, et al.
Publicado: (2020)

Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD(+) acute myeloid leukemia
por: Li, Dan, et al.
Publicado: (2020)

Outcomes of pediatric acute myeloid leukemia patients with FLT3-ITD mutations in the pre-FLT3 inhibitor era
por: Choi, Sujin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6aks15porckt9on6bvdacpjaid